ANNX
Annexon Inc
NASDAQ: ANNX · HEALTHCARE · BIOTECHNOLOGY
$3.94
-4.83% today
Updated 2026-09-11
Market cap
$746.94M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.07
Dividend yield
—
52W range
$2 – $7
Volume
3.2M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-4.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$15.29
+288.07%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.13x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -4.30 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-48.14M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-138.29M | $-134.24M | $-138.20M | $-206.69M | $-55.35M |
| EPS | — | — | — | — | $-1.07 |
| Free cash flow | $-122.83M | $-121.33M | $-118.02M | $-186.49M | $-48.14M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-10 | BLUMENKRANZ, MARK S. | Buy | 175,000 | — |
| 2026-06-11 | YEDNOCK, TED | Sale | 30,646 | — |
| 2026-06-11 | YEDNOCK, TED | Buy | 30,646 | $1.85 |
Peer comparison
Smart narrative
Annexon Inc trades at $3.94. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -4.30, it sits in the distress.
Frequently asked questions
What is Annexon Inc's stock price?
Annexon Inc (ANNX) trades at $3.94.
Is Annexon Inc overvalued?
Annexon Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Annexon Inc (ANNX)?
The 12-month analyst consensus target is $15.29, about 288.1% above the current $3.94. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Annexon Inc's Altman Z-Score is -4.30, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-108.93%
Beta1.22
50D MA$5.31
200D MA$5.40
Shares out0.19B
Float0.16B
Short ratio—
Avg volume3.2M
Performance
1 week-19.10%
1 month-25.52%
3 months-16.35%
YTD-21.51%
1 year—
3 years—
5 years—